Skip Navigation Archive: U.S. Department of Health and Human Services www.hhs.gov
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

AHRQ-Funded Study Shows Increase in Aspirin Use in Patients With Heart Disease, But Underuse is Still a Concern

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Press Release Date: March 8, 2002

A new study funded by the U.S. Agency for Healthcare Research and Quality (AHRQ) found that the percentage of patients with heart disease who report taking aspirin regularly increased from 59 percent to 81 percent between 1995 and 1999. These results reflect substantial improvements in practice, but additional patients could benefit from this inexpensive, effective treatment that reduces deaths from heart disease, recurrent heart attacks, and strokes. The article is being published in the March 15 issue of the American Journal of Cardiology.

Researchers at one of seven AHRQ-supported Centers for Education and Research on Therapeutics (CERTs), the Duke University Medical Center, surveyed more than 25,000 patients from the Duke Databank for Cardiovascular Diseases. They examined trends in aspirin use, patient characteristics, and long-term outcomes for aspirin effectiveness.

Researchers found that patients who didn't take aspirin for reasons related to their heart conditions had nearly twice the risk of dying than those who took the drug regularly.

Study results show a number of clear characteristics that were predictors of aspirin use. Patients more likely to take the drug were younger males, nonsmokers, and those who had suffered prior heart attacks or undergone revascularization procedures in which clogged arteries were unblocked. Those unlikely to take aspirin regularly were patients with heart failure, diabetes, or hypertension.

Clinical trials have consistently shown patients with diabetes benefit more from aspirin than do patients without diabetes.

The AHRQ-supported U.S. Preventive Services Task Force (USPSTF) recently issued a recommendation to clinicians to discuss the benefits and risks of aspirin therapy with healthy adults who are at risk of coronary heart disease. The USPSTF recommendation was published in the January 15 issue of the Annals of Internal Medicine.

The study, "Underuse of Aspirin in a Referral Population with Documented Coronary Artery Disease," is co-authored by Drs. Califf, DeLong, Ostbye, Muhlbaier, and others, at the Duke University Medical Center.

For more information, please contact AHRQ Public Affairs, (301) 427-1364.


 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care